Clinical

Articles

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.


Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer  

Study Shows Increase in Lung Cancer Mortality, Decrease in Diagnosis During COVID-19 Pandemic

“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.


Further Patient Education by Clinicians Is Necessary to Facilitate Better Decision Making

The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.

FDA Grants Breakthrough Therapy Designation to Tiragolumab Combo for PD-L1-High NSCLC

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.

FDA Grants Priority Review to sNDA for Lorlatinib in Previously Untreated ALK+ NSCLC

Videos

The Emory University Winship Cancer Institute expert discussed FDA approvals and other treatment advances that occurred this year.

Jennifer W. Carlisle, MD, Offers Perspective on Lung Cancer Advances in 2020

This study found that among patients with lung cancer from Latin America, Native American ancestry was associated with increased mutations in the EGFR gene, independent of smoking status. 

Latin American Patients with Lung Cancer and Native American Ancestry See Increased EGFR Mutations

Full approval has been granted by the FDA to osimertinib (Tagrisso) for use as adjuvant therapy following tumor resection among patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

FDA Approves Osimertinib as Adjuvant Therapy Following Resection of NSCLC with EGFR Mutations

The American Lung Association’s annual “State of Lung Cancer” (SOLC) report tracked the toll of lung cancer at national and state levels, identifying both promising improvements for the overall population and significant health disparities for racial and ethnic minorities.

Albert Rizzo, MD, on the Annual State of Lung Cancer Report

The FDA granted breakthrough therapy designation to sotorasib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutation, as determined by an FDA-approved test, following at least 1 prior systemic therapy.

Lung Cancer | Topics